Today Mycobacterium avium and Mycobacterium tuberculosis multidrug resistance are responsible for frequent and severe infections in humans and especially in AIDS patients. Irloxacin is a new quinolone derivative, and shows greater activity with an acid pH. It has a good in vitro antimicrobial spectrum against both gram-positive and gram-negative bacteria. We have compared the in vitro activity of irloxacin against mycobacteria (20 M. tuberculosis, 17 M. avium, 5 Mycobacterium bovis, 5 Mycobacterium chelonae, 5 Mycobacterium fortuitum and 1 Mycobacterium gadium) using the Bactec at pH 6.8 and 5.0, with other quinolones (ofloxacin, ciprofloxacin, pefloxacin and 27753 RP). All quinolones tested showed good activity against mycobacteria at pH 6.8 and 5.0. Irloxacin at pH 5.0 had a greater activity against M. avium.

01 Jun 1990·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

In vitro activities of irloxacin and E-3846, two new quinolones

Q2 · MEDICINE

Article

Author: García-Rodríguez, J A ; Muñoz Bellido, J L ; Trujillano, I ; García Sánchez, J E

Irloxacin and E-3846 are two new fluorinated quinolones. We evaluated the activities of these antimicrobial agents, ciprofloxacin, ofloxacin, enoxacin, pefloxacin, norfloxacin, and nalidixic acid against 1,161 bacterial strains. Ciprofloxacin was the most active quinolone. Irloxacin did not show great activity. The activity of E-3846 against gram-negative bacteria was similar to those of ofloxacin and pefloxacin, and E-3846 was the most active quinolone against gram-positive bacteria and anaerobes.

01 Jan 1990·Journal of Antimicrobial ChemotherapyQ2 · MEDICINE

Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.

Q2 · MEDICINE

Article

Author: Van Caekenberghe, D

The in-vitro activities of eight new quinolones (A-56620, amifloxacin, difloxacin, CI-934, enoxacin, irloxacin, pefloxacin, temafloxacin), two reference fluoroquinolones (ciprofloxacin and ofloxacin) and fusidic acid against 147 mycobacterial strains, belonging to seven different species, were compared. Temafloxacin, ofloxacin and ciprofloxacin were the most active compounds. They only showed consistent activity against Mycobacterium tuberculosis, M. malmoense and M. fortuitum, but not against M. chelonei, M. avium, M. intracellulare and M. scrofulaceum. However, individual strains of these species were sometimes susceptible. The best overall in-vitro activity was obtained with temafloxacin, which often showed activity where other products were inactive. Fusidic acid merely displayed good activity against M. tuberculosis (MIC90 16 mg/l).

100 Deals associated with Irloxacin

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Irloxacin

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation